N.Y. Education Law Section 6830
Standardized patient-centered data elements


1.

The commissioner shall develop rules and regulations requiring standardized patient-centered data elements consistent with existing technology and equipment to be used on all prescription medicine dispensed to patients in this state.

2.

When developing the requirements for patient-centered data elements on prescription drug labels, the commissioner shall consider:

(a)

medical literacy research that identifies factors that improve understandability of labels and promotes increased compliance with a drug’s intended use;

(b)

factors that improve the clarity of directions for use;

(c)

font types and sizes;

(d)

inclusion of only patient-centered information; and

(e)

the needs of special populations. To ensure public input, the commissioner shall solicit input from the state board of pharmacy and the state board of medicine, consumer groups, advocates for special populations, pharmacists, physicians, other health care professionals authorized to prescribe, and other interested parties.

Source: Section 6830 — Standardized patient-centered data elements, https://www.­nysenate.­gov/legislation/laws/EDN/6830 (updated Sep. 22, 2014; accessed Oct. 26, 2024).

6800
Introduction
6801
Definition of practice of pharmacy
6801‑A
Collaborative drug therapy management demonstration program
6802
Definitions
6803
Practice of pharmacy and use of title “pharmacist”
6804
State board of pharmacy
6805
Requirements for a professional license
6806
Limited permits
6807
Exempt persons
6808
Registering and operating establishments
6808‑A
Identification of Pharmacists
6808‑B
Registration of nonresident establishments
6810
Prescriptions
6811
Misdemeanors
6811‑A
Certain drugs to be clearly marked or labeled
6811‑B
Door-to-door distribution of drugs prohibited
6811‑C
Patient notification of recalled drugs
6812
Special provisions
6813
Seizure: 1
6814
Records of shipment
6815
Adulterating, misbranding and substituting
6816
Omitting to label drugs, or labeling them wrongly
6816‑A
When substitution is required
6817
New drugs
6818
Adulterated and misbranded cosmetics
6818‑A
Cosmetic samples
6819
Regulations making exceptions
6820
Certification of coal-tar colors for drugs and cosmetics
6821
Poison schedules
6822
Examinations and investigations
6823
Factory inspection
6824
Injunction proceedings
6825
Proof required in prosecution for certain violations
6826
Drug retail price lists
6826‑A
Reducing certain copayments
6827
Mandatory continuing education
6828
Certificates of administration
6829
Interpretation and translation requirements for prescription drugs and standardized medication labeling
6830
Standardized patient-centered data elements
6831
Special provisions relating to outsourcing facilities
6832
Limitations on assistance of an unlicensed person

Accessed:
Oct. 26, 2024

Last modified:
Sep. 22, 2014

§ 6830’s source at nysenate​.gov

Link Style